This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 26/11/2483    most recent 01.ATV.0000244684.23499.bfv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujii, T. Articles by Sueishi, K. Search for Related Content PubMed PubMed Citation Articles by Fujii, T. Articles by Sueishi, K.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2483.)
© 2006 American Heart Association, Inc.

Vascular Biology

Nonendothelial Mesenchymal Cell–Derived MCP-1 Is Required for FGF-2–Mediated Therapeutic Neovascularization

Critical Role of the Inflammatory/Arteriogenic Pathway

Takaaki Fujii; Yoshikazu Yonemitsu; Mitsuho Onimaru; Mitsugu Tanii; Toshiaki Nakano; Kensuke Egashira; Takako Takehara; Makoto Inoue; Mamoru Hasegawa; Hiroyuki Kuwano; Katsuo Sueishi

From the Division of Pathophysiological and Experimental Pathology, Departments of Pathology (T.F., Y.Y., M.O., T.N., T.T., K.S.) and Cardiovascular Medicine (K.E.), Graduate School of Medical Science, Kyushu University, Fukuoka; the Department of General Surgical Science (T.F., H.K.), Graduate School of Medicine, Gunma University, Gunma; and DNAVEC Corporation (M.I., M.H.), Tsukuba, Ibaraki, Japan. Present address for Y.Y.: Department of Gene Therapy at the 21Century Center of Excellence Program, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

Correspondence to Yoshikazu Yonemitsu, MD, PhD, FAHA, Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail yonemitu{at}med.kyushu-u.ac.jp

Objective— Monocyte chemoattractant protein-1 (MCP-1) is a C-C chemokine that is known as an inflammatory/arteriogenic factor. Angiogenesis contributes to the inflammatory process; however, the molecular and cellular mechanisms of the links among the inflammatory pathway, arteriogenesis, and angiogenesis have not been well elucidated.

Methods and Results— Using murine models of fibroblast growth factor-2 (FGF-2)–mediated therapeutic neovascularization, we here show that FGF-2 targets nonendothelial mesenchymal cells (NEMCs) enhancing both angiogenic (vascular endothelial growth factor [VEGF]) and arteriogenic (MCP-1) signals via independent signal transduction pathways. Severe hindlimb ischemia stimulated MCP-1 expression that was strongly enhanced by FGF-2 gene transfer, and a blockade of MCP-1 activity via a dominant negative mutant as well as a deficiency of its functional receptor CCR2 resulted in the diminished recovery of blood flow attributable to adaptive and therapeutic neovascularization. Tumor necrosis factor (TNF)- stimulated MCP-1 expression in all cell types tested, whereas FGF-2–mediated upregulation of MCP-1 was found only in NEMCs but not in others, a finding that was not affected by VEGF in vitro and in vivo.

Conclusions— These results indicate that FGF-2 targets NEMCs independently, enhancing both angiogenic (VEGF) as well as inflammatory/arteriogenic (MCP-1) pathways. Therefore, MCP-1/CCR2 plays a critical role in adaptive and FGF-2–mediated therapeutic neovascularization.

MCP-1 is a C-C chemokine that is an inflammatory/arteriogenic factor. Using murine models of limb ischemia, we show that FGF-2 targets nonendothelial mesenchymal cells (NEMCs) enhancing both angiogenic (VEGF) and arteriogenic (MCP-1) signals via independent signal transduction pathways. Therefore, MCP-1/CCR2 plays a critical role in FGF-2–mediated therapeutic neovascularization.

Key Words: MCP-1 • FGF-2 • arteriogenesis • angiogenesis • mesenchymal cells

This article has been cited by other articles:

				S. Kokubo, K. Nozaki, S. Fukushima, K. Takahashi, K. Miyata, R. Fujimoto, and S. Yokota Recombinant Human Bone Morphogenetic Protein-2 as an Osteoinductive Biomaterial and a Biodegradable Carrier in a Rabbit Ulnar Defect Model Journal of Bioactive and Compatible Polymers, July 1, 2008; 23(4): 348 - 366. [Abstract] [PDF]

				T. Korff, J. Braun, D. Pfaff, H. G. Augustin, and M. Hecker Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment Blood, July 1, 2008; 112(1): 73 - 81. [Abstract] [Full Text] [PDF]

				T. Fujii, M. Onimaru, Y. Yonemitsu, H. Kuwano, and K. Sueishi Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2785 - H2791. [Abstract] [Full Text] [PDF]

				J.-S. Silvestre, Z. Mallat, A. Tedgui, and B. I. Levy Post-ischaemic neovascularization and inflammation Cardiovasc Res, May 1, 2008; 78(2): 242 - 249. [Abstract] [Full Text] [PDF]

				S. M. Vartanian and R. Sarkar Therapeutic Angiogenesis Vascular and Endovascular Surgery, July 1, 2007; 41(3): 173 - 185. [Abstract] [PDF]